Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in Treatment of Insomnia
Insomnia is one of the major challenges in medical science nowadays as it leads to great socio-economic burden by impairing daytime function as well as the development of exhaustion, depression, and memory disturbance in affected individuals. Several important classes of drugs have been tried, inclu...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Revinter Publicações Ltda.
2023-06-01
|
| Series: | Sleep Science |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0043-1770805 |
| _version_ | 1827050644231421952 |
|---|---|
| author | Dwaipayan Sarathi Chakraborty Shouvik Choudhury Sandeep Lahiry |
| author_facet | Dwaipayan Sarathi Chakraborty Shouvik Choudhury Sandeep Lahiry |
| author_sort | Dwaipayan Sarathi Chakraborty |
| collection | DOAJ |
| description | Insomnia is one of the major challenges in medical science nowadays as it leads to great socio-economic burden by impairing daytime function as well as the development of exhaustion, depression, and memory disturbance in affected individuals. Several important classes of drugs have been tried, including the BZDs and non-BZD hypnotics. Available drugs to combat this disease have the limitations of abuse potential, tolerance, and cognitive impairment. In some instances, withdrawal symptoms have been observed upon the abrupt cessation of those drugs. The Orexin system has been very recently targeted as a therapeutic option to overcome those limitations. Treatment of insomnia with Daridorexant as a Dual Orexin Receptor Antagonist (DORA) has been evaluated in several preclinical and clinical studies. Available information obtained from those studies has shown a promising future for this drug in the management of insomnia. Beyond its effectiveness in insomnia, it has been successfully used in patients suffering from obstructive sleep apnoea, chronic obstructed airway disease (COAD), Alzheimer's disease (AD), hypertension, and cardiovascular disorders. Larger studies need to address the safety issues as well as obtain robust pharmacovigilance information to safeguard the risk-benefit aspect of this drug in insomniac adults. |
| first_indexed | 2025-02-18T16:04:25Z |
| format | Article |
| id | doaj.art-5b48a7d33a7c43b19ced8ca2bf99d0e4 |
| institution | Directory Open Access Journal |
| issn | 1984-0659 1984-0063 |
| language | English |
| last_indexed | 2025-02-18T16:04:25Z |
| publishDate | 2023-06-01 |
| publisher | Thieme Revinter Publicações Ltda. |
| record_format | Article |
| series | Sleep Science |
| spelling | doaj.art-5b48a7d33a7c43b19ced8ca2bf99d0e42024-10-24T07:47:38ZengThieme Revinter Publicações Ltda.Sleep Science1984-06591984-00632023-06-01160225626410.1055/s-0043-1770805Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in Treatment of InsomniaDwaipayan Sarathi Chakraborty0Shouvik Choudhury1Sandeep Lahiry2Department of Cardiology & Critical Care Medicine, Belle Vue Clinic, Kolkata, West Bengal, IndiaBurdwan Medical College, Pharmacology, Burdwan, West Bengal, IndiaIndependent Research Scholar, Barasat, Kolkata, West Bengal, IndiaInsomnia is one of the major challenges in medical science nowadays as it leads to great socio-economic burden by impairing daytime function as well as the development of exhaustion, depression, and memory disturbance in affected individuals. Several important classes of drugs have been tried, including the BZDs and non-BZD hypnotics. Available drugs to combat this disease have the limitations of abuse potential, tolerance, and cognitive impairment. In some instances, withdrawal symptoms have been observed upon the abrupt cessation of those drugs. The Orexin system has been very recently targeted as a therapeutic option to overcome those limitations. Treatment of insomnia with Daridorexant as a Dual Orexin Receptor Antagonist (DORA) has been evaluated in several preclinical and clinical studies. Available information obtained from those studies has shown a promising future for this drug in the management of insomnia. Beyond its effectiveness in insomnia, it has been successfully used in patients suffering from obstructive sleep apnoea, chronic obstructed airway disease (COAD), Alzheimer's disease (AD), hypertension, and cardiovascular disorders. Larger studies need to address the safety issues as well as obtain robust pharmacovigilance information to safeguard the risk-benefit aspect of this drug in insomniac adults.http://www.thieme-connect.de/DOI/DOI?10.1055/s-0043-1770805InsomniaDaytimeOrexinToleranceWithdrawalHypnotics |
| spellingShingle | Dwaipayan Sarathi Chakraborty Shouvik Choudhury Sandeep Lahiry Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in Treatment of Insomnia Sleep Science Insomnia Daytime Orexin Tolerance Withdrawal Hypnotics |
| title | Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in Treatment of Insomnia |
| title_full | Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in Treatment of Insomnia |
| title_fullStr | Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in Treatment of Insomnia |
| title_full_unstemmed | Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in Treatment of Insomnia |
| title_short | Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in Treatment of Insomnia |
| title_sort | daridorexant a recently approved dual orexin receptor antagonists dora in treatment of insomnia |
| topic | Insomnia Daytime Orexin Tolerance Withdrawal Hypnotics |
| url | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0043-1770805 |
| work_keys_str_mv | AT dwaipayansarathichakraborty daridorexantarecentlyapproveddualorexinreceptorantagonistsdoraintreatmentofinsomnia AT shouvikchoudhury daridorexantarecentlyapproveddualorexinreceptorantagonistsdoraintreatmentofinsomnia AT sandeeplahiry daridorexantarecentlyapproveddualorexinreceptorantagonistsdoraintreatmentofinsomnia |